BioNTech (BNTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BNTX SEC filings page.
BioNTech (BNTX) reported $3.4B in revenue for fiscal year 2025, up 18.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioNTech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioNTech has an operating margin of -48.9%, meaning the company loses $49 on every $100 of revenue. This results in a profitability score of 8/100. This is down from -47.8% the prior year.
BioNTech's revenue surged 18.3% year-over-year to $3.4B, reflecting rapid business expansion. This strong growth earns a score of 9/100.
With a current ratio of 7.54, BioNTech holds $7.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.
BioNTech converts 9.8% of revenue into free cash flow ($329.7M). This strong cash generation earns a score of 95/100.
BioNTech posts a -5.9% return on equity (ROE), meaning it loses $6 for every $100 of shareholders' equity. This results in a returns score of 23/100. This is down from -3.4% the prior year.
BioNTech scores 6.07, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $22.9B against total liabilities of $3.2B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioNTech passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
BioNTech reported a net loss of $1.3B while generating $535.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
BioNTech reported an operating loss of $1.6B against $16.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BioNTech generated $3.4B in revenue in fiscal year 2025. This represents an increase of 18.3% from the prior year.
BioNTech's EBITDA was -$1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
BioNTech reported a net loss of $1.3B in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
BioNTech earned -$5.52 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
BioNTech generated $329.7M in free cash flow in fiscal year 2025, representing cash available after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
BioNTech held $9.0B in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
BioNTech's gross margin was 77.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.7 percentage points from the prior year.
BioNTech's operating margin was -48.9% in fiscal year 2025, reflecting core business profitability. This is down 1.2 percentage points from the prior year.
BioNTech's net profit margin was -39.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 15.4 percentage points from the prior year.
BioNTech's ROE was -5.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.5 percentage points from the prior year.
Capital Allocation
BioNTech invested $2.5B in research and development in fiscal year 2025. This represents an increase of 5.9% from the prior year.
BioNTech invested $205.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 30.7% from the prior year.
Not reported for fiscal year 2025.
BNTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B+18.3% | $2.8B-32.6% | $4.2B-77.2% | $18.5B-13.8% | $21.5B+3541.2% | $589.9M+383.8% | $121.9M-16.6% | $146.1M+97.4% | $74.1M |
| Cost of Revenue | $753.2M+34.4% | $560.3M-15.6% | $663.5M-79.3% | $3.2B-2.8% | $3.3B+4443.7% | $72.5M+271.3% | $19.5M+24.6% | $15.7M+40.0% | $11.2M |
| Gross Profit | $2.6B+14.3% | $2.3B-35.8% | $3.6B-76.7% | $15.3B-15.8% | $18.2B+3414.7% | $517.3M+405.1% | $102.4M-21.5% | $130.5M+107.6% | $62.9M |
| R&D Expenses | $2.5B+5.9% | $2.3B+18.3% | $2.0B+20.0% | $1.6B+53.1% | $1.1B+36.2% | $788.8M+210.2% | $254.3M+55.2% | $163.9M+59.4% | $102.8M |
| Operating Income | -$1.6Bn/m | -$1.4B-278.1% | $763.7M-94.4% | $13.5B-21.8% | $17.3Bn/m | -$100.8Mn/m | -$203.8Mn/m | -$61.7Mn/m | -$73.7M |
| EBITDA | -$1.2Bn/m | -$1.1B-208.8% | $966.6M-92.9% | $13.7B-21.4% | $17.4Bn/m | -$53.4Mn/m | -$165.7Mn/m | -$36.5Mn/m | -$61.0M |
| Interest Expense | $16.7M-4.7% | $17.5M+110.9% | $8.3M-59.0% | $20.2M-94.1% | $345.3M+334.4% | $79.5M+3440.3% | $2.2M+3983.4% | $55K-99.8% | $31.3M |
| Income Tax | $100.1Mn/m | -$12.8M-104.5% | $283.0M-92.5% | $3.8B-30.0% | $5.4Bn/m | -$196.9Mn/m | -$225K-132.7% | $687K+1170.6% | $54K |
| Net Income | -$1.3Bn/m | -$688.7M-166.9% | $1.0B-89.8% | $10.1B-13.4% | $11.6B+62564.3% | $18.6Mn/m | -$201.1Mn/m | -$55.0Mn/m | -$103.0M |
| EPS (Basic) | -$5.52n/m | -$2.87-167.0% | $4.28-89.7% | $41.49-13.1% | $47.74+64939.9% | $0.07n/m | -$0.95 | N/A | N/A |
| EPS (Diluted) | -$5.52n/m | -$2.87-167.7% | $4.24-89.5% | $40.41-9.9% | $44.85+61007.9% | $0.07n/m | -$0.95 | N/A | N/A |
| Diluted Shares (Avg) | 242M+0.5% | 240M-0.9% | 243M-2.8% | 250M-3.8% | 260M+4.5% | 249M+17.5% | 212M+10.9% | 191M+14.4% | 167M |
Not reported in any period shown, so not listed: SG&A Expenses.
BNTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.8B+10.7% | $23.3B-8.4% | $25.4B+2.2% | $24.9B+39.0% | $17.9B+531.9% | $2.8B+216.6% | $895.5M+19.7% | $748.1M | N/A |
| Current Assets | $18.9B-2.6% | $19.5B-9.9% | $21.6B-7.9% | $23.5B+37.5% | $17.1B+736.8% | $2.0B+224.2% | $628.9M+22.3% | $514.3M | N/A |
| Cash & Equivalents | $9.0B-10.9% | $10.1B-21.7% | $12.9B-13.1% | $14.8B+674.8% | $1.9B+29.4% | $1.5B+154.0% | $582.8M+23.6% | $471.4M+127.8% | $206.9M |
| Inventory | $129.9M-55.7% | $293.2M-25.9% | $395.7M-15.9% | $470.3M-17.3% | $568.7M+625.5% | $78.4M+495.7% | $13.2M+98.4% | $6.6M | N/A |
| Accounts Receivable | $1.1B-28.4% | $1.5B-36.5% | $2.4B-68.8% | $7.6B-45.5% | $14.0B+6823.5% | $202.4M | N/A | N/A | N/A |
| Goodwill | $431.8M+9.6% | $394.0M-1.8% | $401.0M+512.5% | $65.5M+0.1% | $65.4M-0.4% | $65.7M+1864.3% | $3.3M-96.7% | $100.9M+0.4% | $100.4M |
| Total Liabilities | $3.2B+0.5% | $3.2B+5.7% | $3.1B-11.5% | $3.4B-22.6% | $4.5B+284.8% | $1.2B+239.1% | $341.5M-22.8% | $442.2M | N/A |
| Current Liabilities | $2.5B-3.7% | $2.6B+14.0% | $2.3B-27.4% | $3.2B-19.9% | $3.9B+431.7% | $741.1M+377.9% | $155.1M+7.3% | $144.5M | N/A |
| Non-Current Liabilities | $730.1M+18.5% | $616.3M-19.2% | $763.2M+161.4% | $291.9M-43.4% | $515.5M+23.7% | $416.8M+123.6% | $186.4M-37.4% | $297.7M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | $194.2M-31.3% | $282.5M+265.2% | $77.4M | N/A | N/A |
| Total Equity | $22.6B+12.3% | $20.1B-10.3% | $22.4B+4.4% | $21.5B+59.4% | $13.5B+702.4% | $1.7B+202.8% | $554.0M+81.7% | $304.9Mn/m | -$58.0M |
| Retained Earnings | $21.1B+6.6% | $19.8B-9.6% | $21.9B+8.5% | $20.1B+80.1% | $11.2B+2132.9% | $500.9M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
BNTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $535.2M+148.9% | $215.0M-96.4% | $5.9B-59.1% | $14.5B+1342.5% | $1.0Bn/m | -$16.5Mn/m | -$222.9Mn/m | -$67.4Mn/m | -$63.2M |
| Depreciation & Amortization | $449.3M+45.6% | $308.5M+52.0% | $202.9M+53.8% | $131.9M+55.0% | $85.1M+79.8% | $47.3M+24.4% | $38.1M+51.1% | $25.2M+99.0% | $12.7M |
| Capital Expenditures | $205.5M-30.7% | $296.6M+7.5% | $275.9M-21.7% | $352.2M+144.1% | $144.3M+78.8% | $80.7M+86.3% | $43.3M+26.5% | $34.3M+17.2% | $29.2M |
| Free Cash Flow | $329.7Mn/m | -$81.6M-101.4% | $5.7B-60.0% | $14.2B+1542.9% | $862.7Mn/m | -$97.2Mn/m | -$266.2Mn/m | -$101.7Mn/m | -$92.4M |
| Investing Cash Flow | -$2.9Bn/m | -$2.2Bn/m | -$7.7Bn/m | -$37.8Mn/m | -$640.7Mn/m | -$177.1Mn/m | -$86.7Mn/m | -$76.1Mn/m | -$63.2M |
| Financing Cash Flow | -$62.1Mn/m | -$47.5Mn/m | -$861.3Mn/m | -$1.5B-1524.2% | $106.6M-90.3% | $1.1B+154.3% | $430.3M+2.9% | $418.3Mn/m | -$2.0M |
| Dividends Paid | N/A | $0n/m | $0-100.0% | $518.1Mn/m | $0n/m | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.
BNTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6%-2.7pp | 80.3%-4.0pp | 84.3%+1.6pp | 82.7%-2.0pp | 84.7%-3.0pp | 87.7%+3.7pp | 84.0%-5.3pp | 89.3%+4.4pp | 84.9% |
| Operating Margin | -48.9%-1.2pp | -47.8%-65.8pp | 18.1%-54.9pp | 73.0%-7.5pp | 80.5%+97.6pp | -17.1% | -167.1% | -42.2%+57.3pp | -99.5% |
| Net Margin | -39.6%-15.4pp | -24.2%-48.5pp | 24.4%-30.1pp | 54.5%+0.3pp | 54.2%+51.1pp | 3.1% | -164.9% | -37.6% | -139.1% |
| Return on Equity | -5.9%-2.5pp | -3.4%-8.0pp | 4.6%-42.4pp | 47.0%-39.5pp | 86.5%+85.4pp | 1.1%+37.4pp | -36.3%-18.3pp | -18.0% | N/A |
| Return on Assets | -5.2%-2.2pp | -2.9%-7.0pp | 4.0%-36.5pp | 40.5%-24.5pp | 65.0%+64.4pp | 0.7%+23.1pp | -22.4%-15.1pp | -7.3% | N/A |
| Current Ratio | 7.54+0.1x | 7.45-2.0x | 9.43+2.0x | 7.43+3.1x | 4.33+1.6x | 2.75-1.3x | 4.05+0.5x | 3.56 | N/A |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 0.01-0.2x | 0.170.0x | 0.14 | N/A | N/A |
| Liabilities-to-Equity | 0.140.0x | 0.160.0x | 0.140.0x | 0.16-0.2x | 0.33-0.4x | 0.69+0.1x | 0.62-0.8x | 1.45 | N/A |
| Asset Turnover | 0.130.0x | 0.120.0x | 0.17-0.6x | 0.74-0.5x | 1.20+1.0x | 0.21+0.1x | 0.14-0.1x | 0.20 | N/A |
| FCF Margin | 9.8%+12.7pp | -2.9% | 134.1% | 76.5%+72.5pp | 4.0%+20.5pp | -16.5% | -218.3% | -69.6% | -124.8% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioNTech BNTX | FY2025 | $3.4B | -$1.3B | -39.6% | $22.9B | 52/100 |
| Insmed, Inc. INSM | FY2025 | $606.4M | -$1.3B | N/A | $20.5B | 52/100 |
| Genmab A/S GMAB | FY2025 | $3.7B | $963.0M | 25.9% | $24.3B | 77/100 |
| Royalty Pharma plc RPRX | FY2025 | $2.4B | $770.9M | 32.4% | $27.7B | 52/100 |
| Incyte Genomics Inc INCY | FY2025 | $5.1B | $1.3B | 25.0% | $23.0B | 75/100 |
| BeOne Medicines Ltd. ONC | FY2025 | $5.3B | $286.9M | 5.4% | $43.7B | 56/100 |
Where BioNTech Ranks
Frequently Asked Questions
What is BioNTech's annual revenue?
BioNTech (BNTX) reported $3.4B in total revenue for fiscal year 2025. This represents a 18.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioNTech's revenue growing?
BioNTech (BNTX) revenue grew by 18.3% year-over-year, from $2.8B to $3.4B in fiscal year 2025.
Is BioNTech profitable?
No, BioNTech (BNTX) reported a net loss of $1.3B in fiscal year 2025, with a net profit margin of -39.6%.
What is BioNTech's EBITDA?
BioNTech (BNTX) had EBITDA of -$1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BioNTech's gross margin?
BioNTech (BNTX) had a gross margin of 77.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioNTech's operating margin?
BioNTech (BNTX) had an operating margin of -48.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioNTech's net profit margin?
BioNTech (BNTX) had a net profit margin of -39.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioNTech's return on equity (ROE)?
BioNTech (BNTX) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioNTech's free cash flow?
BioNTech (BNTX) generated $329.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioNTech's operating cash flow?
BioNTech (BNTX) generated $535.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioNTech's total assets?
BioNTech (BNTX) had $25.8B in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioNTech's capital expenditures?
BioNTech (BNTX) invested $205.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioNTech spend on research and development?
BioNTech (BNTX) invested $2.5B in research and development during fiscal year 2025.
What is BioNTech's current ratio?
BioNTech (BNTX) had a current ratio of 7.54 as of fiscal year 2025, which is generally considered healthy.
What is BioNTech's liabilities-to-equity ratio?
BioNTech (BNTX) had a liabilities-to-equity ratio of 0.14 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is BioNTech's return on assets (ROA)?
BioNTech (BNTX) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioNTech's P/E ratio?
BioNTech (BNTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $22.9B as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioNTech's price-to-sales ratio?
BioNTech (BNTX) trades at 6.8x sales, its market capitalization divided by $3.4B revenue, FY2025. The market capitalization is $22.9B as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioNTech's Altman Z-Score?
BioNTech (BNTX) has an Altman Z-Score of 6.07, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioNTech's Piotroski F-Score?
BioNTech (BNTX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioNTech's earnings high quality?
BioNTech (BNTX) reported a net loss of $1.3B while generating $535.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioNTech cover its interest payments?
BioNTech (BNTX) reported an operating loss of $1.6B against $16.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioNTech?
BioNTech (BNTX) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.